As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Each year, 500 to 1,000 people in the U.S. are diagnosed with pulmonary arterial hypertension (PAH), a progressive and often under-detected disease. To address the significant impact of this disease ...

Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors ---- Advancement of IkT-001Pro into a ...

Diastolic dysfunction was defined by abnormal diastolic parameters on echocardiography, with HFpEF diagnosis established by ...

Liquidia Technologies ( (LQDA) ) has released its Q3 earnings. Here is a breakdown of the information Liquidia Technologies presented to its ...

“One of our organisation’s primary focus areas is pulmonary hypertension, a chronic condition that affects the heart and ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...